An update on Belimumab for the treatment of lupus

Biologics: Targets and Therapy

Volumn 5, Issue , 2011, Pages 33-43

  Thanou Stavraki, Aikaterini ^a   Sawalha, Amr H ^a,b,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

B lymphocyte stimulator; Belimumab; Lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; PREDNISONE;

ANTIBODY TITER; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL EXPANSION; CELL SURVIVAL; CYTOLOGY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMORAL IMMUNITY; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

EID: 79953193102     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S13804     Document Type: Review

References (49)

1. Merrill JT. Clinical trials for lupus - are we there yet? Bull NYU Hosp Jt Dis. 2009;67(3):267-270.
2. Merrill JT. What was wrong and might now go right with clinical trials for lupus? Curr Rheumatol Rep. 2009;11(4):235-237.
3. Merrill JT, Buyon J P. Rituximab: wanted dead or alive. Arthritis Rheum. 2010;62(8):2188-2191.
4. Baker K P, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003; 48(11):3253-3265.
5. Dörner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363(2):187-197.
6. Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol. 2006;92:1-69.
7. Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulflled? Immunol Rev. 2008; 223:156-174.
8. Treml JF, Hao Y, Stadanlick JE, Cancro M P. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009;53(1):1-16.
9. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
10. Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL 1 transgenic mice. Proc Natl Acad Sci U S A. 2000;97(7):3370-3375.
11. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest. 2006;116(3):724-734.
12. Kahn P, Ramanujam M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 2008; 58(9):2824-2834.
13. Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio M P, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62(5):1457-1468.
14. Stohl W, Jacob N, Guo S, Morel L. Constitutive over expression of BAFF in autoimmune resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010;62(8):2432-2442.
15. Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006; 91(2):586-599.
16. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313-1319.
17. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator over expression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475-3486.
18. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453-2459.
19. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8(1):R6.
20. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10(5):R109.
21. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, place book controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-1178.
22. Petri M, Wallace DJ, Stohl W, et al. SLE patients with active production of anti-nuclear autoantibodies (ANA) have distinct patterns of lupus activity and peripheral B-cell biomarkers compared to ANA negative patients. Ann Rheum Dis. 2006;65 Suppl 2:356.
23. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009; 61(9):1143-1151.
24. Griffths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19(5):685-708.
25. Guidance for Industry: Systemic Lupus Erythematosus - Developing Medical Products for Treatment. Food and Drug Administration; 2006. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf
26. ® (belimumab). Human Genome Sciences. Available from: http://www.hgsi.com/belimumab.html. Accessed November 10, 2010.
27. Phase 3, Multi-Center, Randomized, Double-Blind, Place book Controlled, 52-Wk Study to Evaluate the Effcacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE). NCT00424476. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00424476?term=belimumab&cond=systemic+lupus+erythematosus&rank=1. Accessed November 10, 2010.
28. A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Effcacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE). NCT00410384. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00410384?term=belimumab&cond=systemic+lupus+erythemato sus&rank=2. Accessed November 10, 2010.
29. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined effcacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum. 2010;62 Suppl 10:607.
30. Tanasescu C, Gallacher A, Garcia M, et al. Belimumab, a BLyS-specific inhibitor, significantly improved physical functioning, fatigue, and other health-related quality of life (HRQOL) measures in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis. 2010;69 Suppl 3:556.
31. Navarra S, Ilianova E, Bae SC, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, fares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis. 2010;69 Suppl 3:555.
32. Van Vollenhoven R, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe fares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis. 2010;69 Suppl 3:74.
33. Petri M, Levy RA, Merrill JT, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, fares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum. 2010;62 Suppl 10:190.
34. Furie RA, Zamani O, Wallace DJ, et al. Belimumab, a BLyS specific inhibitor, reduced disease activity and severe fares in seropositive SLE patients: BLISS-76 study results through Wk 76. Arthritis Rheum. 2010;62 Suppl 10:606.
35. Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol. 2007;3(7):407-413.
36. Bertsias GK, Ioannidis J P, Boletis J, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. Ann Rheum Dis. 2009;68(4):477-483.
37. Kiani AN, Petri M. Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep. 2010;12(4):250-258.
38. Strand V, Levy RA, Cervera R, et al. Belimumab, a BLyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE: BLISS-76 and -52 studies. Arthritis Rheum. 2010;62 Suppl 10:773.
39. Levy RA, Ilianova E, Ionescu R, et al. Belimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies and normalized low complement in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis. 2010;69 Suppl 3:556.
40. Stohl W, Hiepe F, Thomas M, et al. Belimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies, normalized low complement, and reduced selected B-cell populations in patients with seropositive systemic lupus erythematosus (SLE): the phase 3 BLISS studies. Arthritis Rheum. 2010;62 Suppl 10:480.
41. Chatham W, Wallace DJ, Stohl W, et al. Effect of belimumab, a B-lymphocyte stimulator-specific inhibitor, on functional antibodies to pneumococcal, tetanus, and influenza vaccines. Arthritis Rheum. 2010; 62 Suppl 10:192.
42. Chatham W, Weinstein A, Petri M, et al. Five-year safety and efficacy experience with belimumab, a BLyS specific inhibitor, in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis. 2010; 69 Suppl 3:147.
43. Merrill JT, Wallace DJ, Furie RA, et al. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Arthritis Rheum. 2010;62 Suppl 10:608.
44. Ginzler EM, Wallace DJ, Chatham W, et al. Belimumab (fully human monoclonal antibody to BLyS) reduced steroid use in systemic lupus erythematosus (SLE) patients during 3 years of therapy. Ann Rheum Dis. 2008;67 Suppl 2:217.
45. Chatham W, Aranow C, Furie R, et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 3 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus (SLE) patients. Ann Rheum Dis. 2008; 67 Suppl 2:217.
46. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-210.
47. A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. NCT00724867. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00724867?term=belimumab&rank=9. Accessed November 10, 2010.
48. A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™) a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057. NCT00712933. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00712933?term=belimumab&rank=11. Accessed November 10, 2010.
49. A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE). NCT00732940. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00732940?term=belimumab&cond=systemic+lupus+erythematosus&rank=3. Accessed November 10, 2010.